Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of the Combination of Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer

NCT00614978 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT00614978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00614978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of the Combination of Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer
Lead sponsor
Jules Bordet Institute
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2008
Completion date
June 30, 2011
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, her2 positive, metastatic breast cancer